Clinical Trials

GastrointestinalOther solid neoplasmSarcomaThoracic

225 enrolled

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT07020221 2026-04-03

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Other solid neoplasmThoracic

49 enrolled 20 charts

Mesothelioma, Malignant

NCT07287995 2026-04-01

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

BreastGenitourinaryThoracic

428 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT05789082 2026-03-19

KRAScendo 170

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT05098132 2026-03-18

SYNERGY-101

364 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06618287 2026-03-17

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

416 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Triple Negative Breast Neoplasms

NCT04165070 2026-03-16

MK-3475-01A

450 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06173505 2026-03-13

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

300 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

215 enrolled 30 charts

BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06162221 2026-03-09

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

616 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06219174 2026-03-06

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Phase 1/2 Suspended

45 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT06772623 2026-02-27

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

252 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05566223 2026-02-23

CheckCell-2

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT02422381 2026-02-18

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03559049 2026-02-12

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT06405230 2026-02-03

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

DermatologicGenitourinaryHead & NeckThoracic

18 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05467748 2026-01-27

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

66 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

61 enrolled 29 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT03003468 2026-01-20

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Phase 1/2 Completed

35 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

37 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02638090 2025-12-22

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

120 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04130516 2025-12-18

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

DermatologicGastrointestinalThoracic

200 enrolled

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

296 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT05860296 2025-12-18

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

36 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03556228 2025-12-11

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma